Selective targeting of angiopoietin-like 3 (ANGPTL3) with vupanorsen for the treatment of patients with familial partial lipodystrophy (FPLD): results of a proof-of-concept study
Sign Up to like & getrecommendations! Published in 2021 at "Lipids in Health and Disease"
DOI: 10.1186/s12944-021-01589-4
Abstract: Background Familial partial lipodystrophy (FPLD) is a rare disease characterized by selective loss of peripheral subcutaneous fat, associated with dyslipidemia and diabetes mellitus. Reductions in circulating levels of ANGPTL3 are associated with lower triglyceride and… read more here.
Keywords: partial lipodystrophy; angptl3 vupanorsen; treatment; familial partial ... See more keywords